Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04242173 · ClinicalTrials.gov registry record · Phase 2
Cemiplimab-rwlc for Unresectable Locally Recurrent and/or Metastatic CSCC
A Phase 2 study, sponsored by H. Lee Moffitt Cancer Center and Research Institute.
- Terminated
- Registry status
- Phase 2
- Development phase
- 3
- Enrollment target
NCT04242173 is a Phase 2 study that was terminated before completion, run by H. Lee Moffitt Cancer Center and Research Institute. The registered enrollment target is 3 participants.
The verdict
NCT04242173, a Phase 2 study, was terminated before completion, sponsored by H. Lee Moffitt Cancer Center and Research Institute.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 3 participants
- Enrollment target
Study Summary
The purpose of this research study is to determine how people with weakened immune systems and unresectable (cannot be removed by surgery) locally recurrent and/or metastatic cutaneous squamous cell carcinoma (CSCC) respond to study treatment with Cemiplimab. Cemiplimab is approved for sale in United States by the U.S. Food and Drug Administration (FDA).
Interventions
- DRUG Cemiplimab-Rwlc
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3 participants |
| Start Date | 2020-06-25 |
| Est. Completion | 2022-05-26 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04242173
The ClinicalTrials.gov registry entry for NCT04242173 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 3 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is H. Lee Moffitt Cancer Center and Research Institute, which has 502 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Cemiplimab-Rwlc is the first listed.
NCT04242173 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04242173 about?
NCT04242173 is a clinical study titled "Cemiplimab-rwlc for Unresectable Locally Recurrent and/or Metastatic CSCC". The purpose of this research study is to determine how people with weakened immune systems and unresectable (cannot be removed by surgery) locally recurrent and/or metastatic cutaneous squamous cell carcinoma (CSCC) respond to study treatment with Cemiplimab. Cemiplimab is approved for sale in Unite...
What is the current status of trial NCT04242173?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 3 participants. The study started on 2020-06-25. Estimated completion is 2022-05-26.
What interventions are being tested in trial NCT04242173?
The interventions under investigation include: Cemiplimab-Rwlc (DRUG).
Who is sponsoring clinical trial NCT04242173?
This trial is sponsored by H. Lee Moffitt Cancer Center and Research Institute, which has 502 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.